# Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients

> **NCT06610643** · NA · NOT_YET_RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 40 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2
- Immunocompromised

## Interventions

- **DRUG:** combination therapy
- **DRUG:** SOC

## Key facts

- **NCT ID:** NCT06610643
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-21
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06610643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06610643, "Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06610643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*